ARCH PATHOL LAB MED:反馈在患者护理至关重要

2019-02-06 MedSci MedSci原创

反馈是基于直接观察的信息传递,旨在提高性能。学习是反馈的核心,因此,反馈是病理学住院医师教育的必备能力。在实验室环境中,实验室专业人员在所有实践环境和经验水平上提供和接收反馈的能力对工作流程和最终的患者护理至关重要。本研究的目标是总结反馈的重要性,优化反馈交换的策略,克服提供和接收反馈的障碍。 研究人员通过审查同行评审的原始文章,评论文章,医学教育文献和出版的反馈和沟通书籍,以探索提供和接收

反馈是基于直接观察的信息传递,旨在提高性能。学习是反馈的核心,因此,反馈是病理学住院医师教育的必备能力。在实验室环境中,实验室专业人员在所有实践环境和经验水平上提供和接收反馈的能力对工作流程和最终的患者护理至关重要。本研究的目标是总结反馈的重要性,优化反馈交换的策略,克服提供和接收反馈的障碍。

研究人员通过审查同行评审的原始文章,评论文章,医学教育文献和出版的反馈和沟通书籍,以探索提供和接收反馈的理想方法,并确定反馈交换的常见障碍。

医学教育文献强调反馈的技巧,描述了在医学实践中反馈交流经常遇到的障碍。有效的反馈需要仔细考虑给予者、接受者和环境。同样,这些因素都会对反馈交换造成障碍。已经描述了提供反馈的各种方法。所有的反馈都应该针对特定的行为,本质上是非评价性的,然后是对理解的确认和行动计划。目前,很少有文章描述接受反馈的重要性。接受反馈可能是有一定难度的,但是通过学习倾听和在执行所听到的信息时做出有意识的决定,反馈会得到加强。通过练习,提供和接收反馈变得更容易。

原始出处:

Rachel Jug, Xiaoyin “Sara” Jiang, Giving and Receiving Effective Feedback: A Review Article and How-To Guide

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786261, encodeId=4e101e862613f, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Apr 11 21:35:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609563, encodeId=24a4160956343, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 13:35:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360146, encodeId=812d36014686, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Feb 07 21:36:12 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360104, encodeId=06b636010469, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/05/292ec65fcc7ce718d5eea3f96838a269.jpg, createdBy=add32542695, createdName=Dans.ru, createdTime=Thu Feb 07 10:30:52 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360080, encodeId=fe5d36008036, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 07 00:11:01 CST 2019, time=2019-02-07, status=1, ipAttribution=)]
    2019-04-11 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786261, encodeId=4e101e862613f, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Apr 11 21:35:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609563, encodeId=24a4160956343, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 13:35:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360146, encodeId=812d36014686, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Feb 07 21:36:12 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360104, encodeId=06b636010469, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/05/292ec65fcc7ce718d5eea3f96838a269.jpg, createdBy=add32542695, createdName=Dans.ru, createdTime=Thu Feb 07 10:30:52 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360080, encodeId=fe5d36008036, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 07 00:11:01 CST 2019, time=2019-02-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786261, encodeId=4e101e862613f, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Apr 11 21:35:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609563, encodeId=24a4160956343, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 13:35:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360146, encodeId=812d36014686, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Feb 07 21:36:12 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360104, encodeId=06b636010469, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/05/292ec65fcc7ce718d5eea3f96838a269.jpg, createdBy=add32542695, createdName=Dans.ru, createdTime=Thu Feb 07 10:30:52 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360080, encodeId=fe5d36008036, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 07 00:11:01 CST 2019, time=2019-02-07, status=1, ipAttribution=)]
    2019-02-07 清风拂面

    谢谢分享学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1786261, encodeId=4e101e862613f, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Apr 11 21:35:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609563, encodeId=24a4160956343, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 13:35:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360146, encodeId=812d36014686, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Feb 07 21:36:12 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360104, encodeId=06b636010469, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/05/292ec65fcc7ce718d5eea3f96838a269.jpg, createdBy=add32542695, createdName=Dans.ru, createdTime=Thu Feb 07 10:30:52 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360080, encodeId=fe5d36008036, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 07 00:11:01 CST 2019, time=2019-02-07, status=1, ipAttribution=)]
    2019-02-07 Dans.ru

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1786261, encodeId=4e101e862613f, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Apr 11 21:35:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609563, encodeId=24a4160956343, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 13:35:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360146, encodeId=812d36014686, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Feb 07 21:36:12 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360104, encodeId=06b636010469, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/05/292ec65fcc7ce718d5eea3f96838a269.jpg, createdBy=add32542695, createdName=Dans.ru, createdTime=Thu Feb 07 10:30:52 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360080, encodeId=fe5d36008036, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Feb 07 00:11:01 CST 2019, time=2019-02-07, status=1, ipAttribution=)]
    2019-02-07 smartxiuxiu

    0

相关资讯

INT J LAB HEMATOL:隐性骨髓增生异常综合征(MDS):一项确定或排除病因不明的贫血患者中MDS的前瞻性研究

骨髓增生异常综合征(MDSs)的诊断可能是复杂的,特别是当仅仅出现贫血时。本研究目的是探讨贫血和/或病因不明的大红细胞症的主要原因。研究人员在3个血液学实验室进行为期4个月的多中心前瞻性研究。在步骤1中,使用一个自动化的信息学系统来筛查137 453例贫血和/或大红细胞症患者的血象(n = 2702)。在步骤2中,研究人员排除了所有贫血似乎是由已知原因引起的患者。这使得290名贫血患者的病因不明。

家属说没有病,医生却吓掉魂!这个病例为所有人敲响警钟!

类似的“陷阱”在门诊,尤其是在急诊时常有之,因为绝大多数患者和家属缺乏基础医学常识,而且对自己的身体健康有着盲目的自信!

JCLA:原发性干燥综合征患者唇腺淋巴细胞的免疫表型及临床特点

本研究的目的是探讨原发性干燥综合征(pSS)患者唇腺淋巴细胞免疫表型与外周血免疫表型的一致性。 研究人员选取71例pSS患者和35例颌面部外伤患者作为研究对象。根据71例pSS患者唇腺CD20与CD3比值,将其分为高表达组(48例)和低表达组(23例)。分析唇腺淋巴细胞免疫表型、病程、红细胞沉降率(ESR)、C反应蛋白、免疫球蛋白和补体水平。结果表明,pSS组唇腺IgG、IgA、IgM、C3

JCLA:中国汉族散发性乳腺癌患者白细胞介素18基因启动子区域多态性与易感性的相关性分析

白介素18 (IL 18)基因位于染色体11 q22.2 22.3,1,它包含许多单核苷酸多态性(single nucleotide polymorsms, SNPs),尤其是在启动子区域。在各种癌症中,白细胞介素18 137G/C, 607G/T多态性发挥多种作用。然而,关于白介素18 (IL 18)基因多态性与绝经期体重指数(body mass index, BMI)之间相互作用的研究还存在争

INT J LAB HEMATOL:利用CD81/CD58的表达率很容易从B细胞祖细胞急性淋巴细胞白血病患者淋巴母细胞中识别造血细胞

由于存在血细胞生成素(HG),通过多参数流式细胞术(MFC)鉴别白血病淋巴母细胞(LB)对B细胞祖细胞急性淋巴细胞白血病(BCP-ALL)的诊断和随访目前仍比较困难。本研究的目的是比较BCP-ALL和HG的淋巴母细胞表达最具鉴别力的抗原。 · 2019-02-01

-->

癌症新药试验成患者“救命稻草”年需5万人,专家提示风险

能够相继入组两个新药的临床试验,肺癌患者张小羽(化名)认为是非常幸运的一件事。“如果没有新药临床试验,我肯定用不起这么好的药。”张小羽对澎湃新闻(www.thepaper.cn)说。国内还未上市的新药,正在成为许多像张小羽一样晚期癌症患者的“救命稻草”。“晚期肿瘤病人,能够参与(新药)临床试验是一个特别好的治疗手段,因为现有的治疗水平已经到这了,想突破就只能等新药上市,新药上市一般都得好几年以